Table 2 Description of delivery settings that were defined for the purpose of modelling uterotonic coverage in status quo and intervention scenarios. The uterotonics used for prevention of PPH (in non-operative deliveries) at each setting in status quo and intervention scenarios are specified
| Â | Setting 1 | Setting 2 | Setting 3 | Setting 4 | Setting 5 |
|---|---|---|---|---|---|
Tertiary-level public facilities | Secondary-level public facilities | Primary health facilities and non-facility births attended by a skilled provider | Non-facility births not attended by a skilled provider | Private sector deliveries | |
Settings included in each country | |||||
Bangladesh | Medical Colleges, Specialised hospitals, District hospitals | Upazilla health complex, Maternal and child welfare centres | Union sub-centres, Rural sub-centres, Union health and family welfare centres, Community clinics, out-of-facility deliveries attended by a medically trained provider | Out-of-facility deliveries attended by a TBA, trained TBA, relative, no-one or other. | Private healthcare facilities |
Ethiopia | Specialist hospitals, General hospitals, Primary hospitals | Health centres | Deliveries attended by a HEW (health post or out of facility) | Out-of-facility deliveries attended by a TBA, trained TBA, relative, no-one or other. | Private healthcare facilities |
Uterotonic used for PPH prevention (non-operative deliveries) in status quo | |||||
Bangladesh | Injectable oxytocin | Injectable oxytocin | Injectable oxytocin or misoprostol | Misoprostol | Injectable oxytocin |
Ethiopia | Injectable oxytocin | Injectable oxytocin | Misoprostol | None | Injectable oxytocin |
Uterotonic used for PPH prevention (non-operative deliveries) in intervention scenarioa | |||||
Bangladesh | Inhaled oxytocin | Inhaled oxytocin | Inhaled oxytocin | Inhaled oxytocin | Injectable oxytocin |
Ethiopia | Inhaled oxytocin | Inhaled oxytocin | Inhaled oxytocin | None | Injectable oxytocin |